BOJI CRO(300404) Sou Hu Cai Jing·2025-04-07 10:24Group 1 - The core viewpoint of the article highlights the significant decline in the stock price of Boji Pharmaceutical, which closed at 8.27 yuan, down 19.47%, with a rolling PE ratio of 71.04 times and a total market value of 3.168 billion yuan [1] - Boji Pharmaceutical ranks 35th in the medical services industry, which has an average PE ratio of 45.72 times and a median of 41.83 times [1] - As of September 30, 2024, the number of shareholders in Boji Pharmaceutical decreased by 4,424 to 22,995, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Boji Pharmaceutical primarily provides comprehensive "one-stop" CRO services for domestic and international pharmaceutical companies and research institutions, including clinical research services, preclinical research services, CDMO services, and technology transfer services [1] - The company has received several accolades, including being ranked 8th among the "Top 20 Chinese Pharmaceutical CROs in 2024" and recognized as a "Top 50 Chinese Pharmaceutical R&D Company in 2023" [1] - In the latest financial report for Q3 2024, Boji Pharmaceutical achieved a revenue of 555.6 million yuan, representing a year-on-year increase of 55.01%, and a net profit of 43.28 million yuan, up 87.98%, with a gross profit margin of 32.19% [1]